Clinicians should be alert for invasive serogroup Y meningococcal disease in at-risk populations and those with unusual symptoms amid the highest annual number of cases reported since 2014, according ...

"The key take-home message is that whether and how meningococcal B vaccines are being used vary widely across countries. It is also worth noting that protein-based MenB vaccines have not been approved ...

Two recombinant MenB vaccines (4CMenB and rLP2086) have been developed and the 4CMenB vaccine has been approved in Europe and soon will likely be approved for use in Canada. These newer vaccines will ...

Please provide your email address to receive an email when new articles are posted on . The CDC issued a health alert for invasive meningococcal disease caused by Neisseria meningitidis serogroup Y.

Anyone old enough to remember the devastation wrought by meningococcal sepsis or meningitis welcomed the introduction of quadrivalent meningococcal vaccine, which provides protection against the A, C, ...

Vaccine recommended to help protect persons over 10 years old in the United States (US) against disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one ...

An effective, affordable, multivalent meningococcal conjugate vaccine is needed to prevent epidemic meningitis in the African meningitis belt. Data on the safety and immunogenicity of NmCV-5, a ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss ...

It’s a good thing that you advised that my grandnephews be given a shot of the meningococcal B vaccine.” The message had come from a colleague who learned about the outbreak in Kent. Receiving it ...